论文部分内容阅读
目的:评价我院糖尿病合并社区获得性肺炎(CAP)患者抗菌药物的应用特点及合理性。方法:抽取我院2009年1月-2010年6月所有糖尿病合并CAP患者的病历,以临床治疗效果及药物利用指数(DUI)为评价指标,对其抗菌药物的应用情况进行统计、分析。结果:用药频度最高的为喹诺酮类,其次为头孢菌素类(含加酶抑制剂)。临床治疗有效率为86.21%。DUI为0.9～1.1的有17种,占60.71%;DUI<0.9的有5种,占17.86%;DUI>1.1的有6种,占21.43%。结论:我院糖尿病合并CAP患者抗感染治疗以喹诺酮类和β-内酰胺类为主,临床效果肯定,抗菌药物应用基本合理,但仍存在部分药物频繁换药、日剂量及给药频次不规范等问题,应加强监管。
Objective: To evaluate the characteristics and rationality of antibacterials in diabetic patients with community-acquired pneumonia (CAP) in our hospital. Methods: The records of all patients with diabetes mellitus complicated with CAP were collected from January 2009 to June 2010 in our hospital. The clinical therapeutic effect and drug use index (DUI) were used as evaluation indexes to analyze the application of antibiotics. Results: The highest frequency of quinolones, followed by cephalosporins (including enzyme inhibitors). The effective rate of clinical treatment was 86.21%. There are 17 species with DUI ranging from 0.9 to 1.1, accounting for 60.71%; 5 species with DUI <0.9, accounting for 17.86%; and 6 species with DUI> 1.1 accounting for 21.43%. Conclusion: In our hospital, patients with diabetes mellitus and CAP with anti-infective therapy mainly quinolones and β-lactams, clinical effect is affirmed, and the application of antibacterial drugs is basically reasonable, but there are still some frequent drug dressing changes, irregular daily dosage and frequency of administration And other issues, should strengthen supervision.